Study links complement activity to IgA kidney disease severity
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study looks at how parts of the immune system (called complement) may relate to how severe IgA kidney disease is. It may help doctors understand disease activity better, even if the study is mainly observational.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (male or female).
- You have been diagnosed with IgA nephropathy confirmed by a kidney biopsy.
- You can be included whether your diagnosis is new or long ago, and whether kidney function is good or reduced.
- You can join whether you have had a kidney transplant before or not.
- You are followed by the Nephrology Department at Strasbourg University Hospital.
- You can sign an informed consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how certain immune cells in blood relate to IgA nephropathy, a kidney condition. It may help doctors understand which patients are likely to do better and guide future care.
This study looks at a specific type of antibody called IgA in patients with certain kidney diseases. It aims to understand which IgA antibodies cause kidney damage, which could help develop better treatments.
This trial tests an experimental drug called ADX-038 for people with certain types of kidney disease that are driven by the complement system (a part of the immune system). The study aims to see if ADX-038 can help slow down or improve kidney function.
This trial looks at how bacteria in the gut (microbiome) and substances in the body (metabonomics) relate to IgA nephropathy, a kidney condition. The goal is to understand patterns that may help explain the disease and improve future care.
This study tests an experimental drug called SGB-9768 for people with certain kidney diseases that involve complement protein deposits. The goal is to see if it can reduce kidney damage and protein loss in urine.
This trial tests a medicine called CM313 in people with IgA nephropathy, a kidney disease. It may help reduce protein in the urine, which is a sign of kidney damage.
Hear when a new IgA Nephropathy Severity in Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.